Zoledronic acid (Zometa)
Also known as Aclasta, Reclast, zoledronate, or Zomera.
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Zoledronic acid (Zometa) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on pages 21-22 of the Zoledronic acid (Zometa) package insert[1]
- Zoledronic acid (Zometa) patient drug information (UpToDate)[5]